(Total Views: 206)
Posted On: 09/26/2022 3:25:08 PM
Post# of 14
NetworkNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase 2b proof-of-concept data, which we believe demonstrates that anti-TNF therapy can prevent the progression of Dupuytren’s disease in its early stages, as well as plans for two additional phase 2 studies, one in frozen shoulder, which has recently commenced, and the other in post-operative cognitive delirium (‘POCD’), for which we just received grant funding,” Dr. Woody stated in the letter. “In closing, we continue to work diligently and efficiently to deliver treatment options for one of the largest drivers of disease, inflammation. Our active clinical development program currently consists of three potential indications and our clinical development plans for all ongoing programs remain on track. We believe that the successful execution of our current clinical development plans over the long-term could enhance stockholder value.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today released a letter to stockholders from its Chief Executive Officer Dr. James Woody. In the letter, Dr. Woody discussed the company’s continued status to remain on track with clinical development plans. “Currently, we have an active clinical development program that includes phase 2a and phase 2b proof-of-concept data, which we believe demonstrates that anti-TNF therapy can prevent the progression of Dupuytren’s disease in its early stages, as well as plans for two additional phase 2 studies, one in frozen shoulder, which has recently commenced, and the other in post-operative cognitive delirium (‘POCD’), for which we just received grant funding,” Dr. Woody stated in the letter. “In closing, we continue to work diligently and efficiently to deliver treatment options for one of the largest drivers of disease, inflammation. Our active clinical development program currently consists of three potential indications and our clinical development plans for all ongoing programs remain on track. We believe that the successful execution of our current clinical development plans over the long-term could enhance stockholder value.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
